At the end of the latest market close, Can-Fite BioPharma Ltd. (CANF) was valued at $1.90. In that particular session, Stock kicked-off at the price of $1.88 while reaching the peak value of $2.19 and lowest value recorded on the day was $1.87. The stock current value is $1.97.
Recently in News on December 3, 2020, Can-Fite to Present at Benzinga Global Small Cap Conference on December 8, 2020. Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that the Company’s CEO Dr. Pnina Fishman will present at Benzinga’s inaugural Global SmallCap Conference on Tuesday, December 8, 2020 at 3:00 pm ET on Track 2. Investors interested in viewing Can-Fite’s presentation may register with free access here for the two-day conference which takes place virtually from December 8-9, 2020. You can read further details here
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Can-Fite BioPharma Ltd. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $4.0000 on 01/07/20, with the lowest value was $1.0800 for the same time period, recorded on 02/12/20.
Can-Fite BioPharma Ltd. (CANF) full year performance was -43.55%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Can-Fite BioPharma Ltd. shares are logging -51.49% during the 52-week period from high price, and 82.41% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.08 and $4.06.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 3285731 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Can-Fite BioPharma Ltd. (CANF) recorded performance in the market was -40.30%, having the revenues showcasing 7.65% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 30.37M, as it employees total of 8 workers.
Analysts verdict on Can-Fite BioPharma Ltd. (CANF)
During the last month, 0 analysts gave the Can-Fite BioPharma Ltd. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.9629, with a change in the price was noted -0.4700. In a similar fashion, Can-Fite BioPharma Ltd. posted a movement of -19.26% for the period of last 100 days, recording 640,710 in trading volumes.
Can-Fite BioPharma Ltd. (CANF): Technical Analysis
Raw Stochastic average of Can-Fite BioPharma Ltd. in the period of last 50 days is set at 56.90%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 52.17%. In the last 20 days, the company’s Stochastic %K was 49.56% and its Stochastic %D was recorded 42.67%.
Let’s take a glance in the erstwhile performances of Can-Fite BioPharma Ltd., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -40.30%. Additionally, trading for the stock in the period of the last six months notably improved by 8.24%, alongside a downfall of -43.55% for the period of the last 12 months. The shares increased approximately by 4.23% in the 7-day charts and went up by -3.86% in the period of the last 30 days. Common stock shares were driven by 7.65% during last recorded quarter.